Loading...
XSHG600867
Market cap2.19bUSD
Dec 27, Last price  
8.20CNY
1D
0.24%
1Q
0.00%
Jan 2017
-55.13%
Name

Tonghua Dongbao Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600867 chart
P/E
13.69
P/S
5.20
EPS
0.60
Div Yield, %
3.10%
Shrs. gr., 5y
-0.65%
Rev. gr., 5y
2.69%
Revenues
3.08b
+10.69%
307,843,217329,681,239401,615,308469,970,343551,042,670573,853,265637,797,301784,499,202991,527,7851,204,240,3791,451,340,0771,669,312,4482,040,394,5392,545,324,9622,692,927,4822,777,148,8792,892,169,2383,267,897,4642,778,453,0593,075,416,029
Net income
1.17b
-26.17%
016,195,75312,061,59677,433,09646,823,25673,715,101178,365,254363,981,45362,708,212183,913,362279,780,914492,958,977640,923,429836,553,622838,605,479811,206,148929,916,0451,308,254,2121,581,891,7361,167,835,317
CFO
862m
-0.18%
13,165,30392,228,315158,001,245120,942,82692,313,973166,196,168160,399,3450194,319,415221,055,351205,890,089294,578,586725,763,119961,185,868876,935,3951,152,169,7351,192,286,1081,134,548,060863,094,112861,521,518
Dividend
May 23, 20240.25 CNY/sh
Earnings
Mar 27, 2025

Profile

Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company operates through Pharmaceutical Industry and Building Materials Industry segments. Its lead product portfolio includes insulin analogues, such as insulin glargine, Insulin aspart, and insulin lispro; antidiabetic drugs; and oral hypoglycemic drugs, as well as Gan Shulin pens, blood glucose meters, and other medical devices. It offers building materials. The company has a strategic alliance with Adocia. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is based in Tonghua, China.
URL
http://www.thdb.com/
IPO date
Aug 24, 1994
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,075,416
10.69%
2,778,453
-14.98%
3,267,897
12.99%
Cost of revenue
1,445,037
1,742,623
1,824,524
Unusual Expense (Income)
NOPBT
1,630,379
1,035,830
1,443,374
NOPBT Margin
53.01%
37.28%
44.17%
Operating Taxes
197,974
247,687
225,857
Tax Rate
12.14%
23.91%
15.65%
NOPAT
1,432,404
788,143
1,217,516
Net income
1,167,835
-26.17%
1,581,892
20.92%
1,308,254
40.69%
Dividends
(495,933)
(1,095,782)
(425,038)
Dividend yield
2.31%
6.06%
1.90%
Proceeds from repurchase of equity
77,435
BB yield
-0.35%
Debt
Debt current
150,000
(21,085)
(7,892)
Long-term debt
2,650
2,650
Deferred revenue
28,530
28,672
Other long-term liabilities
27,508
2,650
Net debt
(1,543,960)
(1,168,983)
(1,328,195)
Cash flow
Cash from operating activities
861,522
863,094
1,134,548
CAPEX
(348,126)
Cash from investing activities
(321,992)
343,990
34,059
Cash from financing activities
(223,953)
FCF
1,094,254
459,052
1,091,332
Balance
Cash
1,159,721
846,524
902,040
Long term investments
534,239
304,023
420,913
Excess cash
1,540,189
1,011,625
1,159,558
Stockholders' equity
5,701,403
6,212,642
5,779,779
Invested Capital
5,853,604
5,534,843
4,972,474
ROIC
25.16%
15.00%
25.38%
ROCE
22.03%
15.80%
23.54%
EV
Common stock shares outstanding
1,979,382
1,970,741
2,044,147
Price
10.83
17.97%
9.18
-16.24%
10.96
-18.09%
Market cap
21,436,706
18.49%
18,091,399
-19.25%
22,403,853
-17.17%
EV
19,897,832
16,927,727
21,081,007
EBITDA
1,816,253
1,186,999
1,587,026
EV/EBITDA
10.96
14.26
13.28
Interest
7,214
283
226
Interest/NOPBT
0.44%
0.03%
0.02%